F. Delorme
- Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management 3
- Periodontics top 5%
- Oral microbiology and periodontitis research 3
-
- Cancer Treatment and Pharmacology 5
- Neutropenia and Cancer Infections 2
- HER2/EGFR in Cancer Research 2
- Dermatology top 10%
-
- Breast Cancer Treatment Studies 2
-
- Glycosylation and Glycoproteins Research 1
-
- Advanced Breast Cancer Therapies 1
F. Delorme
16 papers receiving 456 citations
Peers
Comparison fields: 5 of 62
- Internal Medicine 200
- Periodontics 62
- Cardiology and Cardiovascular Medicine 152
- Oncology 168
- Dermatology 44
Countries citing papers authored by F. Delorme
This map shows the geographic impact of F. Delorme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Delorme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Delorme more than expected).
Fields of papers citing papers by F. Delorme
This network shows the impact of papers produced by F. Delorme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Delorme. The network helps show where F. Delorme may publish in the future.
Co-authorship network
The 25 scholars most cited alongside F. Delorme, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1998 | 15 | |
| 2 | 1997 | 4 | |
| 3 | Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. | 1997 | 24 |
| 4 | 1997 | 5 | |
| 5 | Prevention of Venous Thromboembolism after Knee Arthroplasty | 1996 | 25 |
| 6 | 1996 | 5 | |
| 7 | 1996 | 137 | |
| 8 | 1992 | 178 | |
| 9 | 1992 | 15 | |
| 10 | 1989 | 6 | |
| 11 | 1989 | 47 | |
| 12 | 1988 | 14 | |
| 13 | Chemotherapy with daunorubicin-anti-CEA conjugates in human colon adenocarcinoma grafted in nude mice. | 1984 | 2 |
| 14 | Daunorubicin-albumin copolymer targeting to leukemic cells in vitro and in vivo. | 1984 | 5 |
| 15 | 1980 | 13 | |
| 16 | [Dissecting aneurysm and rupture of the aorto secondary to giant-cell aortitis. Case report and review of the literature]. | 1970 | 2 |
About F. Delorme
F. Delorme is a scholar working on Internal Medicine, Periodontics and Oncology, having authored 16 papers that have together received 497 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Oral microbiology and periodontitis research (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers), Neutropenia and Cancer Infections (2 papers), Breast Cancer Treatment Studies (2 papers), HER2/EGFR in Cancer Research (2 papers), Glycosylation and Glycoproteins Research (1 paper) and Advanced Breast Cancer Therapies (1 paper). The work is most often cited by research in Internal Medicine (200 citations), Periodontics (62 citations) and Cardiology and Cardiovascular Medicine (152 citations). F. Delorme has collaborated with scholars based in Canada and India. Frequent co-authors include Louis Desjardins, Jacques R. Leclerc, William Geerts, F Laroche, F Jobin, F Letendre, B. Norris, Theodore A. Vandenberg, W. Lofters and Elizabeth A. Eisenhauer. Their work appears in journals such as Journal of the American Society of Echocardiography, Journal of Clinical Oncology, Annals of Internal Medicine, Investigational New Drugs and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.